Skip navigation

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis

Lee, HJ, Jeong, G, Li, H, Kim, M, Kim, J, Park, SJ, Han, YJ, Lee, KH, Kronbichler, A, Hong, SH, Ghayda, RA, Luchini, C, Nottegar, A, Koyanagi, A, Smith, L, Jacob, L, Dragioti, E, Radua, J, Cargnin, S, Terrazzino, S, Thompson, Trevor ORCID: 0000-0001-9880-782X, Yon, DK, Lee, SW, Yang, JM, Wasuwanich, P, Shin, JL and Gamerith, G (2021) Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences. ISSN 1128-3602 (In Press)

[img] PDF (Author's accepted manuscript)
33164_THOMPSON_Efficacy_and_safety_of epidermal growth.pdf - Accepted Version
Restricted to Repository staff only

Download (416kB) | Request a copy

Abstract

OBJECTIVE: It is controversial whether there is efficacy or safety benefit of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy. We aim to assess the efficacy and safety of EGFR-TKIs compared to other chemotherapeutics in EGFR-mutated NSCLC.
MATERIALS AND METHODS: Up to April 27th, 2020, PubMed, Embase, Medline, Scopus, Cochrane library, and ClinicalTrials.gov were searched with the following keywords: “non-small cell lung cancer” AND “advanced” AND “epidermal growth factor receptor” AND “tyrosine kinase inhibitor” AND “randomized controlled trials.” After filtering, 230 eligible studies were initially identified. Data extraction followed PRISMA and included outcomes were progression-free survival (PFS), overall survival (OS), and severe adverse event (SAE). Direct and indirect meta-analyses were generated in the context of log-linear mixed-effects models, with fixed effects for each relative comparison and random effects for each study.
RESULTS: The results showed that EGFR-TKI therapy had improved PFS with a hazard ratio (HR) of 0.40 (95% CI: 0.36-0.44, p<0.001) compared to standard chemotherapy. Nevertheless, the EGFR-TKIs showed no benefit of OS (HR: 0.96, 95% CI: 0.83-1.10, p=0.556). In the analysis of adverse events, EGFR-TKIs had fewer SAEs than standard chemotherapy (HR: 0.29, 95% CI: 0.26-0.33, p<0.001).
CONCLUSIONS: Our systemic review indicates that EGFR-TKI therapy has improved PFS and reduced SAEs compared to standard chemotherapy in advanced EGFR-mutated NSCLC.

Item Type: Article
Uncontrolled Keywords: NSCLC; EGFR-TKI; efficacy; safety; meta-analysis
Subjects: Q Science > QD Chemistry
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Faculty / School / Research Centre / Research Group: Faculty of Education, Health & Human Sciences
Faculty of Education, Health & Human Sciences > Department of Psychology, Social Work & Counselling
Faculty of Education, Health & Human Sciences > Institute for Lifecourse Development
Faculty of Education, Health & Human Sciences > Institute for Lifecourse Development > Centre for Chronic Illness and Ageing
Related URLs:
Last Modified: 23 Sep 2021 13:54
Selected for GREAT 2016: None
Selected for GREAT 2017: None
Selected for GREAT 2018: None
Selected for GREAT 2019: None
Selected for REF2021: None
URI: http://gala.gre.ac.uk/id/eprint/33164

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics